Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$92 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.2
Industry P/E
--
EV/EBITDA
-1.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-2
Face value
--
Shares outstanding
35,985,700
CFO
$-142.98 Mln
EBITDA
$-167.39 Mln
Net Profit
$-161.39 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Immuneering Corp (IMRX)
| 26.8 | 81.2 | 55.0 | 95.1 | -18.3 | -- | -- |
|
BSE Sensex
| 4.9 | 0.4 | 6.7 | 6.3 | 16.2 | 18.3 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
Immuneering Corp (IMRX)
| -69.8 | 51.5 | -70.0 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Immuneering Corp (IMRX)
|
2.8 | 92.1 | 0.7 | -61.8 | -8,843.2 | -124.1 | -- | 2.2 |
| 49.8 | 7,821.1 | 1,208.8 | 131.7 | 13.4 | 6.3 | 60.1 | 3.9 | |
| 128.2 | 8,290.2 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 147.2 | 7,242.1 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 52.2 | 10,001.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 44.9 | 11,009.2 | 2,298.9 | 643.6 | 35.4 | 29.2 | 18.4 | 5.2 | |
| 53.9 | 6,507.3 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14 | 13.5 | |
| 313.5 | 8,891.5 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.6 | 15.0 | |
| 26.8 | 10,016.6 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 127.3 | 12,524.1 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.9 | 4.9 |
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical... trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Address: 245 Main Street, Cambridge, MA, United States, 02142 Read more
Co-Founder, President, CEO & Director
Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Co-Founder, President, CEO & Director
Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Immuneering Corp (IMRX) stood at $ 56 Mln as on 31-Mar-25
The share price of Immuneering Corp (IMRX) is $2.79 (NASDAQ) as of 24-Jun-2025 12:40 EDT. Immuneering Corp (IMRX) has given a return of -18.32% in the last 3 years.
Immuneering Corp (IMRX) has a market capitalisation of $ 92 Mln as on 23-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Immuneering Corp (IMRX) is 2.20 times as on 23-Jun-2025, a 21% discount to its peers’ median range of 2.79 times.
Since, TTM earnings of Immuneering Corp (IMRX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Immuneering Corp (IMRX) and enter the required number of quantities and click on buy to purchase the shares of Immuneering Corp (IMRX).
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Address: 245 Main Street, Cambridge, MA, United States, 02142
The CEO & director of Dr. Benjamin J. Zeskind M.B.A., Ph.D.. is Immuneering Corp (IMRX), and CFO & Sr. VP is Dr. Benjamin J. Zeskind M.B.A., Ph.D..
There is no promoter pledging in Immuneering Corp (IMRX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,260
|
|
|
1,128
|
|
|
991
|
|
|
988
|
|
|
870
|
|
|
829
|
|
|
809
|
|
|
742
|
|
|
664
|
| Immuneering Corp (IMRX) | Ratios |
|---|---|
|
Return on equity(%)
|
-124.09
|
|
Operating margin(%)
|
-8843.21
|
|
Net Margin(%)
|
-8505.1
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Immuneering Corp (IMRX) was $0 Mln.
$0.35
(
